TY - JOUR
T1 - Epigenetic regulation in Parkinson’s disease
AU - Labbé, Catherine
AU - Lorenzo-Betancor, Oswaldo
AU - Ross, Owen A.
N1 - Funding Information:
The authors would like to thank all those who have contributed to our research, particularly the patients and families who donated DNA samples and brain tissue for this work. The Mayo Clinic is a Morris K. Udall Parkinson’s Disease Research Center of Excellence (NINDS P50 NS072187), an Alzheimer’s disease Research Center (NIA P50 AG16574) and is supported by The Little Family Foundation, the Mangurian Foundation for Lewy body research and the Mayo Clinic AD and related dementias genetics program. OAR is supported by NINDS R01 NS078086 and The Michael J. Fox Foundation. CL is the recipient of a FRSQ postdoctoral fellowship and is a 2015 Younkin Scholar supported by the Mayo Clinic Alzheimer’s Disease and Related Dementias Genetics program. The authors would like to thank Dr. Jungsu Kim for his careful review of the manuscript and Ms. Mariana Ruiz Villarreal for her design of the neuron used in Fig. .
Publisher Copyright:
© 2016, Springer-Verlag Berlin Heidelberg.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Recent efforts have shed new light on the epigenetic mechanisms driving gene expression alterations associated with Parkinson’s disease (PD) pathogenesis. Changes in gene expression are a well-established cause of PD, and epigenetic mechanisms likely play a pivotal role in regulation. Studies in families with PD harboring duplications and triplications of the SNCA gene have demonstrated that gene dosage is associated with increased expression of both SNCA mRNA and protein, and correlates with a fulminant disease course. Furthermore, it is postulated that even subtle changes in SNCA expression caused by common variation is associated with disease risk. Of note, genome-wide association studies have identified over 30 loci associated with PD with most signals located in non-coding regions of the genome, thus likely influencing transcript expression levels. In health, epigenetic mechanisms tightly regulate gene expression, turning genes on and off to balance homeostasis and this, in part, explains why two cells with the same DNA sequence will have different RNA expression profiles. Understanding this phenomenon will be crucial to our interpretation of the selective vulnerability observed in neurodegeneration and specifically dopaminergic neurons in the PD brain. In this review, we discuss epigenetic mechanisms, such as DNA methylation and histone modifications, involved in regulating the expression of genes relevant to PD, RNA-based mechanisms, as well as the effect of toxins and potential epigenetic-based treatments for PD.
AB - Recent efforts have shed new light on the epigenetic mechanisms driving gene expression alterations associated with Parkinson’s disease (PD) pathogenesis. Changes in gene expression are a well-established cause of PD, and epigenetic mechanisms likely play a pivotal role in regulation. Studies in families with PD harboring duplications and triplications of the SNCA gene have demonstrated that gene dosage is associated with increased expression of both SNCA mRNA and protein, and correlates with a fulminant disease course. Furthermore, it is postulated that even subtle changes in SNCA expression caused by common variation is associated with disease risk. Of note, genome-wide association studies have identified over 30 loci associated with PD with most signals located in non-coding regions of the genome, thus likely influencing transcript expression levels. In health, epigenetic mechanisms tightly regulate gene expression, turning genes on and off to balance homeostasis and this, in part, explains why two cells with the same DNA sequence will have different RNA expression profiles. Understanding this phenomenon will be crucial to our interpretation of the selective vulnerability observed in neurodegeneration and specifically dopaminergic neurons in the PD brain. In this review, we discuss epigenetic mechanisms, such as DNA methylation and histone modifications, involved in regulating the expression of genes relevant to PD, RNA-based mechanisms, as well as the effect of toxins and potential epigenetic-based treatments for PD.
KW - Acetylation
KW - Epigenetics
KW - Histones
KW - Methylation
KW - Parkinson’s disease
KW - RNA-based epigenetic mechanisms
UR - http://www.scopus.com/inward/record.url?scp=84976351592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976351592&partnerID=8YFLogxK
U2 - 10.1007/s00401-016-1590-9
DO - 10.1007/s00401-016-1590-9
M3 - Review article
C2 - 27358065
AN - SCOPUS:84976351592
SN - 0001-6322
VL - 132
SP - 515
EP - 530
JO - Acta neuropathologica
JF - Acta neuropathologica
IS - 4
ER -